Qiongding Medical Secures Tens of Millions in Pre-A Funding to Advance TI-Based Non-Invasive Deep Brain Neuromodulation

VCBeat learned that recently, Neurodome, Inc. (hereinafter referred to as "Neurodome"), an innovative hard-tech enterprise focusing on non-invasive deep brain neuromodulation, announced the completion of a multi-million yuan Pre-A round of financing. This follows the angel round of financing completed earlier this year with Frees Fund and Shunwei Capital, marking another round of financing officially announced by Neurodome in a short period. This round of financing was jointly led by Shaanxi Growth Enterprise Leading Fund Co., Ltd and Oriza Holdings, with participation from China-Singapore Suzhou Industrial Park Development Group CO.LTD., Xi'an Finance Investment Management Co., Ltd., and Xi'an Talent Development Fund Partnership (Limited Partnership), along with continued investment from existing shareholders. The funds will be used to iterate and optimize Temporal Interference (TI) stimulation technology and accelerate product registration for various indications.

Since its establishment in November 2019, Neurodome, Inc. has conducted thousands of animal experiments, theoretical validations, algorithm simulations, and parameter calibrations around TI technology, forming a TI stimulation solution at an internationally and domestically leading level. Neurodome, Inc. adheres to clinical needs as the highest guidance, collaborating with more than ten top hospitals such as Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and Tangdu Hospital of Air Force Medical University, carrying out a large number of clinical trials, and has achieved clinical results exceeding expectations, bringing new solutions for non-invasive treatment of various neurological/psychiatric disorders.

The brain is known as the most complex object in the universe and the source of thoughts, emotions, perception, behavior, learning, and memory. However, when it comes to diseases in this "final frontier" of natural science, what humanity can achieve remains very limited. Currently, China has nearly 130 million patients suffering from various brain-related diseases, reflecting an enormous demand for treatment. For instance, there are over 50 million people with depression, more than 3 million with Parkinson's disease, and nearly 10 million with Alzheimer's disease. The burden caused by brain diseases accounts for 23% of the total disease burden. In response, neuromodulation—characterized by its minimally invasive (or non-invasive) nature, high targeting precision, high reversibility, and long-term adjustability—has emerged as an effective clinical intervention. However, existing deep-brain neuromodulation solutions predominantly rely on invasive craniotomy, while non-invasive interventions struggle to balance depth and accuracy, failing to meet clinical expectations in terms of effectiveness. This highly promising multi-billion-dollar blue ocean market urgently calls for a new technology leader capable of simultaneously fulfilling the clinical needs for non-invasiveness, deep-brain access, precision, and multi-targeting.

Neurodome, Inc. has been deeply engaged in the field of neuromodulation, continuously refining TI technology, and is the first in China to practically master and achieve precise non-invasive deep brain neuromodulation in humans using TI. The latest sixth-generation products, TIs EMO-1000/TIs CAP, feature ultra-high precision stimulation control, capable of accurately outputting various modes of stimulation signals. Parameters can be finely adjusted according to clinical needs, ensuring the accuracy, effectiveness, and repeatability of treatment plans. These products can perfectly achieve non-invasive, deep brain, high-precision, multi-target central nervous system stimulation interventions and can be widely applied in the treatment of various neurological/psychiatric disorders.

Professor Yiru Fang, Director of the Department of Psychology at Ruijin HospitalEvaluation: In the treatment and intervention of mental disorders such as depression, existing antidepressant drugs have hit a bottleneck, with their efficacy showing a "ceiling" effect. Therefore, physical treatments based on neuromodulation technology are highly clinically promising at this stage.

Professor Lu Yong, Director of the Brain Disease Center at Ruijin HospitalEvaluation: The development of TI technology is targeted research and development aimed at addressing unmet clinical needs. Demand-driven innovation can better meet the clinical market.

Dr. Wu Yiwen, Director of the Department of Neurology at Ruijin HospitalEvaluation: Brain stimulation technology has demonstrated good application effects in movement disorders, and the non-invasive stimulation technology of TI brings greater application prospects.

Dr. Zhang Chencheng, Deputy Director of the Brain Center at Ruijin HospitalEvaluation: DBS has shown very significant effects. However, according to a survey published by Tiantan Hospital, the current penetration rate of DBS in China is only 1.1%. Most patients still prefer non-invasive therapies. Therefore, non-invasive deep brain modulation represented by TI has greater clinical potential.

The Sixth-Generation Non-Invasive Deep Brain Neuromodulation Products TIs EMO-1000/TIs CAP

Regarding the successful financing this time, Founder and CEO Dr. Li LongIt is reported that in the current market environment, investors' continued optimism towards Neurodome stems from the company's solid foundational research and development, market advancement, and the significant potential value inherent in TI technology itself. The new funding will be utilized to expand the exploration of indications for TI technology in the field of neuromodulation and to conduct clinical trials.

Regarding this round of financing,Dr. Guo Jia, Managing Director of Shaanxi Growth Enterprise Leading Fund Co., Ltd.TI technology has achieved non-invasive deep brain stimulation, combining the characteristics of spatial targeting and non-invasiveness. It can simultaneously meet clinical needs such as being non-invasive, deep-brain, high-precision, and multi-targeted, effectively solving bottlenecks of existing technologies. It demonstrates remarkable efficacy, safety, and compliance in the treatment of neuropsychiatric disorders such as depression, epilepsy, Alzheimer's disease, Parkinson's disease, and insomnia. It is a powerful scientific tool to advance brain science and is expected to lead the development trend in this field. Neurodome, Inc. possesses an internationally top-tier team of technical experts and an efficient execution team, building a moat from hardware, algorithms to clinical value, promoting continuous product updates and iterations. As a pioneer in non-invasive deep brain neuromodulation, the company looks forward to its products benefiting more patients.

Fei Jianjiang, Managing Partner of Oriza HoldingsThe brain has an extremely important impact on human health, but to this day, brain science remains one of the most challenging frontiers in scientific research. Oriza Holdings continues to focus on the latest discoveries and applications in the field of brain science and has invested in companies such as Ladder Medical, which develops implantable brain-computer interfaces; MotionCare, which innovates digital therapies for brain science; and NeuroX Bio, which focuses on neuronal repair. Temporal Interference (TI) is a highly anticipated groundbreaking new therapy. Neurodome has the world’s most advanced accumulation of TI technology and is also one of the teams with the longest history of TI research in China. We look forward to the Neurodome team bringing innovative, non-invasive therapies to patients across various deep-brain disease fields.

Dr. Xie Da, Investment Vice President of Frees FundThe brain is the "ultimate frontier" of life science research; with the aging population and changes in the pace of social life, the demand for diagnosis and treatment of neuropsychiatric disorders may remain consistently high. Neuromodulation serves not only as an efficient research tool to understand the brain but also as a powerful therapy gradually emerging for treating brain diseases. Temporal Interference (TI) technology is one of the few innovative techniques in the field of neuromodulation that combines non-invasive, deep-brain, precise, and multi-target characteristics. Neurodome has been deeply committed to this technology for many years, completing product prototyping, technical validation, and actively exploring applications in mental illnesses, neurodegenerative diseases, and other areas. As the angel round investor of Neurodome, FreeS Fund continues to focus on cutting-edge technologies in the field of brain science and anticipates significant breakthroughs by the company in brain research, disease treatment, and even the broader field of brain technology.

Li Rui, Partner of Shunwei CapitalIt has been less than a year since the last round of investment, and Neurodome has made significant progress in both product development and team building. In clinical settings, the range of indications applicable to TI technology continues to expand, and clinical experts have given high praise to non-invasive deep brain neuromodulation technology. Additionally, the company has innovative pipelines such as radiofrequency and ultrasound in the field of neuromodulation. We look forward to Neurodome maintaining its first-mover advantage, driving breakthroughs in the clinical application of non-invasive deep brain neuromodulation technology, and becoming an innovative hard-tech dark horse with distinct characteristics in the field of neuromodulation. We believe that the Neurodome team will continue to develop more excellent products, create greater clinical value in the field of neuromodulation, and bring more hope to patients.

With dreams in heart, the road lies beneath our feet. In the future, Neurodome will continue to focus on the iteration of TI technology, with deep brain modulation at its core, launching a multi-physical factor modulation product line that covers the functional cortex and central-peripheral nervous system, and building a globally leading non-invasive deep brain neuromodulation platform based on TI stimulation.